Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Hopes To Gain Broad Market For Tecentriq In Adjuvant NSCLC

Interim ASCO Data Show Improvement in PD-L1 Expressors, All-Comers

Executive Summary

An executive told Scrip the company hopes to target all-comers as well as PD-L1-positive patients.

You may also be interested in...



Keytruda Adjuvant Kidney Cancer Data Cement The Future Of IO

The data illustrate the growing importance of adjuvant settings of solid tumors for PD-1/PD-L1 inhibitors, which could make up more than one-quarter of their sales in 2025.

Finance Watch: IPO Momentum Slows But Biopharma Stocks Get An ASCO Bump

Public Company Edition: There was just one initial public offering during the past two weeks, but another biotech-focused SPAC went public and Gingko Bioworks announced a high-value SPAC merger. Also, Insmed and Dynavax offerings led recent public company financings.

Merck & Co.’s Keytruda Gets Fighting Chance In TNBC

The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel